Tag: influenza vaccines market

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Influenza Vaccines Market CAGR Outlook And Future Development

The influenza vaccines market has experienced substantial expansion in recent years. This market is projected to increase from $9.04 billion in 2025 to $9.71 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.4%. Historically, this expansion resulted from factors such as the increasing prevalence of seasonal influenza, a limited public awareness during the early 2000s, the widespread use of trivalent vaccines, insufficient global manufacturing capacity, and a dependence on conventional egg-based production methods.

Projections indicate significant expansion for the influenza vaccines market size in the coming years. This market is projected to reach $13.13 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 7.8%. This anticipated growth during the forecast period can be primarily linked to the wider acceptance of quadrivalent vaccines, the broadening scope of precision medicine approaches, an increase in governmental vaccination programs, advancements in cell-based and recombinant vaccine technologies, and improvements in cold chain and distribution networks. Key trends anticipated during this period encompass the refinement of seasonal vaccine formulations, the growth of pediatric immunization initiatives, a rise in government-backed flu vaccination drives, the incorporation of new adjuvants to boost immunogenicity, and an expansion of vaccine delivery options in home and outpatient settings.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=84543780&type=smp&name=Influenza%20Vaccines%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Influenza Vaccines Market Growth Backed By Core Demand Fundamentals

The influenza vaccine market is anticipated to expand due to increasing seasonal influenza occurrences. Seasonal influenza is defined as a respiratory illness caused by influenza viruses that commonly circulate and lead to infections during particular times of the year, typically in colder months. This increase is a result of antigenic drift, population susceptibility, various environmental factors, incomplete vaccine coverage, and the absence of universal vaccination. Influenza vaccines play a crucial role in lowering the incidences of seasonal influenza by providing immunization against the circulating strains of the virus. For instance, in November 2023, the Centers for Disease Control and Prevention (CDC) reported that the 2022-2023 flu season saw approximately 31 million flu-related illnesses, 14 million flu-related medical visits, 360,000 flu-related hospitalizations, and 21,000 flu-related deaths. Therefore, the rising incidences of seasonal influenza are directly fueling the growth of the influenza vaccines market.

Influenza Vaccines Market Segment Analysis: What Are The Core Market Categories?

The influenza vaccines market covered in this report is segmented –

1) By Vaccine Type: Inactivated, Live Attenuated

2) By Valency: Quadrivalent, Trivalent

3) By Route Of Administration: Injection, Nasal Spray

4) By Age Group: Pediatric, Adult

5) By Distribution Channel: Hospitals And Pharmacies, Government And Institutional Supply, Other Distribution Channels

Subsegments:

1) By Inactivated: Trivalent Inactivated Vaccines (TIV), Quadrivalent Inactivated Vaccines (QIV)

2) By Live Attenuated: Live Attenuated Influenza Vaccines (LAIV), Quadrivalent Live Attenuated Influenza Vaccines (QLAIV)

Influenza Vaccines Market Growth Trends Reshaping The Competitive Landscape

Major companies in the influenza vaccine market are adopting advanced product innovations, such as quadrivalent seasonal influenza vaccines, to strengthen their respiratory vaccine franchise and financial profile. A quadrivalent seasonal influenza vaccine is engineered to protect against four different flu viruses, specifically two influenza A viruses and two influenza B viruses. For instance, in September 2023, Clover Biopharmaceuticals Ltd., a biotechnology company based in China, launched AdimFlu-S (QIS), a quadrivalent seasonal influenza vaccine. This vaccine represents the sole imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The quadrivalent composition of the vaccine improves its capability to achieve high vaccine effectiveness, irrespective of which influenza B strain becomes seasonally prevalent, when compared to trivalent options.

Influenza Vaccines Market Top Companies Driving Competitive Growth

Major companies operating in the influenza vaccines market are Pfizer Inc., Merck & Co Inc., Sanofi-Aventis LLC, GlaxoSmithKline plc, Serum Institute of India Private Limited, Seqirus Inc., CSL Limited, Daiichi Sankyo Company Limited, Moderna Inc., Novavax AB, Bharat Biotech International Limited, Valneva SE, Shionogi & Co Ltd., Sinovac Biotech Co Ltd., Walvax Biotechnology Co Ltd., Hualan Biological Engineering Inc., China National Pharmaceutical Group Corporation, Green Cross Corporation, Mitsubishi Tanabe Pharma Corporation, Osivax, Vaxess Technologies Inc., Gamma Vaccines Pty Ltd

View The Full Influenza Vaccines Market Report:

https://thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Influenza Vaccines Market Geographic Spread And Regional Opportunities

North America was the largest region in the influenza vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Influenza Vaccines Market Growth Potential: How Will Market Size Change Through 2030?

The market for influenza vaccines has experienced robust expansion over the recent years, with projections indicating an increase from $9.04 billion in 2025 to $9.71 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.4%. Historically, this growth has been driven by factors such as the higher incidence of seasonal influenza, minimal public knowledge during the early 2000s, a dominance of trivalent vaccine formulations, limited worldwide production capabilities, and a dependence on conventional egg-based manufacturing techniques.

The influenza vaccines market is poised for significant expansion over the coming years, with projections indicating it will reach $13.13 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.8%. This anticipated growth in the forecast timeframe is driven by factors such as the rising preference for quadrivalent vaccines, a broader application of precision medicine strategies, heightened government-led vaccination efforts, the advancement of cell-based and recombinant vaccine technologies, and improvements in cold chain logistics and distribution networks. Key developments shaping this period include the refinement of seasonal vaccine formulations, the broadening of pediatric immunization initiatives, an uptick in publicly funded flu vaccination drives, the introduction of novel adjuvants to boost immune responses, and a growing trend toward home-based and outpatient vaccine administration.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11935&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Influenza Vaccines Market Demand Drivers: What Is Fueling Industry Growth?

The growing frequency of seasonal influenza cases is expected to drive expansion in the influenza vaccine market moving forward. Seasonal influenza is defined as a respiratory condition triggered by influenza viruses that typically spread and lead to infections during particular times of the year, predominantly in the colder months. This trend has developed due to factors such as antigenic drift, population vulnerability, environmental conditions, insufficient vaccine coverage, and the absence of a universal vaccination program. Influenza vaccines contribute to reducing seasonal influenza occurrences by offering protection against the currently circulating viral strains. In November 2023, the Centers for Disease Control and Prevention (CDC), a government agency based in the United States, reported that during the 2022-2023 flu season, approximately 31 million flu-related illnesses took place, alongside 14 million flu-related medical consultations, 360,000 flu-related hospitalizations, and 21,000 flu-related deaths. Consequently, the increasing prevalence of seasonal influenza episodes is fueling growth in the influenza vaccines market.

Influenza Vaccines Market Segments: Where Are The Largest Growth Opportunities?

The influenza vaccines market covered in this report is segmented –

1) By Vaccine Type: Inactivated, Live Attenuated

2) By Valency: Quadrivalent, Trivalent

3) By Route Of Administration: Injection, Nasal Spray

4) By Age Group: Pediatric, Adult

5) By Distribution Channel: Hospitals And Pharmacies, Government And Institutional Supply, Other Distribution Channels

Subsegments:

1) By Inactivated: Trivalent Inactivated Vaccines (TIV), Quadrivalent Inactivated Vaccines (QIV)

2) By Live Attenuated: Live Attenuated Influenza Vaccines (LAIV), Quadrivalent Live Attenuated Influenza Vaccines (QLAIV)

Influenza Vaccines Market Innovation Trends: Which Developments Are Transforming The Industry?

Leading players in the influenza vaccine market are increasingly embracing cutting-edge product innovations, specifically quadrivalent seasonal influenza vaccines, as a strategy to enhance both their respiratory vaccine portfolio and financial standing. Designed to offer protection against four distinct flu viruses—two influenza A strains and two influenza B strains—this vaccine type provides broader coverage. A notable example occurred in September 2023, when Clover Biopharmaceuticals Ltd., a biotechnology firm headquartered in China, introduced AdimFlu-S (QIS), a quadrivalent seasonal influenza vaccine. As the only imported quadrivalent option of its kind approved for use in China among individuals aged three and older, it stands out. Its quadrivalent formulation enhances its capacity to deliver strong vaccine effectiveness, regardless of which influenza B strain dominates in a given season, offering a clear advantage over trivalent alternatives.

Influenza Vaccines Market Major Participants And Competitive Dynamics

Major companies operating in the influenza vaccines market are Pfizer Inc., Merck & Co Inc., Sanofi-Aventis LLC, GlaxoSmithKline plc, Serum Institute of India Private Limited, Seqirus Inc., CSL Limited, Daiichi Sankyo Company Limited, Moderna Inc., Novavax AB, Bharat Biotech International Limited, Valneva SE, Shionogi & Co Ltd., Sinovac Biotech Co Ltd., Walvax Biotechnology Co Ltd., Hualan Biological Engineering Inc., China National Pharmaceutical Group Corporation, Green Cross Corporation, Mitsubishi Tanabe Pharma Corporation, Osivax, Vaxess Technologies Inc., Gamma Vaccines Pty Ltd

Access The Complete Influenza Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Influenza Vaccines Market Geographic Analysis: Where Is Demand Growing The Fastest?

North America was the largest region in the influenza vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Forecasted Rise In Market Size Of The Influenza Vaccines Market During The Forecast Period?

The influenza vaccines market has seen strong growth over recent years. It is anticipated to increase from $9.04 billion in 2025 to $9.71 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.4%. This historical expansion can be ascribed to the rising prevalence of seasonal influenza, limited public awareness in early 2000s, predominance of trivalent vaccines, low global manufacturing capacity, and reliance on traditional egg-based production methods.

The influenza vaccines market size is anticipated to experience robust expansion in the near future. It is set to increase to $13.13 billion in 2030, achieving a compound annual growth rate (CAGR) of 7.8%. This growth over the forecast period can be attributed to the rising acceptance of quadrivalent vaccines, the widening application of precision medicine techniques, increasing government-led vaccination campaigns, the evolution of cell-based and recombinant vaccines, and improved cold chain and distribution systems. Significant trends expected during this period include optimizing seasonal vaccine formulations, extending pediatric immunization initiatives, a surge in government-funded flu vaccination programs, the incorporation of novel adjuvants for improved immunogenicity, and an increase in home-based and outpatient vaccine delivery methods.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11935&type=smp

Which Core Factors Are Supporting The Expansion Of The Influenza Vaccines Market?

The increasing occurrence of seasonal influenza is anticipated to fuel the expansion of the influenza vaccine market moving ahead. Seasonal influenza is defined as a respiratory sickness brought on by influenza viruses that commonly spread and lead to infections during particular periods annually, typically in colder seasons. This progression stems from factors such as antigenic drift, population vulnerability, environmental elements, insufficient vaccine coverage, and the absence of widespread vaccination. Influenza vaccines contribute to diminishing the instances of seasonal influenza by offering immunity against the currently circulating viral strains. For instance, in November 2023, the Centers for Disease Control and Prevention (CDC), a US-based governmental body, disclosed that the 2022-2023 flu season saw roughly 31 million flu-associated illnesses, 14 million flu-related medical appointments, 360,000 flu-associated hospital admissions, and 21,000 flu-related fatalities. Consequently, the escalating occurrences of seasonal influenza are propelling the growth of the influenza vaccines market.

What Are The Major Segment Categories Within The Influenza Vaccines Market?

The influenza vaccines market covered in this report is segmented –

1) By Vaccine Type: Inactivated, Live Attenuated

2) By Valency: Quadrivalent, Trivalent

3) By Route Of Administration: Injection, Nasal Spray

4) By Age Group: Pediatric, Adult

5) By Distribution Channel: Hospitals And Pharmacies, Government And Institutional Supply, Other Distribution Channels

Subsegments:

1) By Inactivated: Trivalent Inactivated Vaccines (TIV), Quadrivalent Inactivated Vaccines (QIV)

2) By Live Attenuated: Live Attenuated Influenza Vaccines (LAIV), Quadrivalent Live Attenuated Influenza Vaccines (QLAIV)

What Trends Are Shaping The Influenza Vaccines Market Structure?

Leading companies operating in the influenza vaccine market are implementing advanced product innovations, such as quadrivalent seasonal influenza vaccines, to enhance their respiratory vaccine offerings and financial standing. A quadrivalent seasonal influenza vaccine is formulated to protect against four different flu viruses, including two influenza A viruses and two influenza B viruses. For instance, in September 2023, Clover Biopharmaceuticals Ltd., a China-based biotechnology company, launched AdimFlu-S (QIS), a quadrivalent seasonal influenza vaccine. This vaccine is notably the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The vaccine’s quadrivalent composition improves its capability to achieve high vaccine effectiveness, regardless of which influenza B strain becomes seasonally prevalent, especially when compared to trivalent options.

Who Are The Companies Shaping The Influenza Vaccines Market Landscape?

Major companies operating in the influenza vaccines market are Pfizer Inc., Merck & Co Inc., Sanofi-Aventis LLC, GlaxoSmithKline plc, Serum Institute of India Private Limited, Seqirus Inc., CSL Limited, Daiichi Sankyo Company Limited, Moderna Inc., Novavax AB, Bharat Biotech International Limited, Valneva SE, Shionogi & Co Ltd., Sinovac Biotech Co Ltd., Walvax Biotechnology Co Ltd., Hualan Biological Engineering Inc., China National Pharmaceutical Group Corporation, Green Cross Corporation, Mitsubishi Tanabe Pharma Corporation, Osivax, Vaxess Technologies Inc., Gamma Vaccines Pty Ltd

Access The Complete Influenza Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Which Region Holds The Largest Share In The Influenza Vaccines Market?

North America was the largest region in the influenza vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Influenza Vaccines Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=11935&type=smp

Browse Through More Reports Similar to the Global Influenza Vaccines Market 2026, By The Business Research Company

Influenza Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Influenza Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Influenza Vaccines Market Between 2026 And 2030?

The influenza vaccines market has experienced robust growth in recent years. It is projected to expand from $9.04 billion in 2025 to $9.71 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.4%. The historical expansion can be attributed to several factors including the rising prevalence of seasonal influenza, limited public awareness during the early 2000s, the widespread use of trivalent vaccines, low global manufacturing capacity, and reliance on traditional egg-based production methods.

The influenza vaccines market is anticipated to experience robust expansion in the coming years. This market is projected to reach $13.13 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. This future growth is largely driven by factors such as the rising use of quadrivalent vaccines, advancements in precision medicine, a surge in government-led vaccination programs, innovations in cell-based and recombinant vaccine technology, and improvements in cold chain and distribution networks. Key trends anticipated during this period encompass the refinement of seasonal vaccine formulations, the broadening of pediatric immunization efforts, an uptick in government-sponsored flu vaccination drives, the integration of new adjuvants to boost immune response, and the expansion of vaccine administration in home and outpatient settings.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11935&type=smp

Which Key Drivers Are Affecting The Influenza Vaccines Market Development?

The increasing occurrences of seasonal influenza are anticipated to drive the expansion of the influenza vaccine market moving ahead. Seasonal influenza is defined as a respiratory sickness brought on by influenza viruses that commonly spread and lead to infections at certain periods annually, generally in cooler seasons. This trend stems from antigenic drift, the vulnerability of populations, environmental elements, insufficient vaccine penetration, and the absence of widespread immunization. Influenza vaccines contribute to lowering the frequency of seasonal influenza by offering protection against the prevalent viral strains. As an illustration, in November 2023, the Centers for Disease Control and Prevention (CDC), a US government organization, stated that for the 2022-2023 flu period, around 31 million flu-associated illnesses, 14 million flu-associated medical appointments, 360,000 flu-associated hospital admissions, and 21,000 flu-associated fatalities occurred. Consequently, the growing frequency of influenza seasons is fueling the expansion of the influenza vaccines market.

How Is The Influenza Vaccines Market Segmented Across Different Segment Categories?

The influenza vaccines market covered in this report is segmented –

1) By Vaccine Type: Inactivated, Live Attenuated

2) By Valency: Quadrivalent, Trivalent

3) By Route Of Administration: Injection, Nasal Spray

4) By Age Group: Pediatric, Adult

5) By Distribution Channel: Hospitals And Pharmacies, Government And Institutional Supply, Other Distribution Channels

Subsegments:

1) By Inactivated: Trivalent Inactivated Vaccines (TIV), Quadrivalent Inactivated Vaccines (QIV)

2) By Live Attenuated: Live Attenuated Influenza Vaccines (LAIV), Quadrivalent Live Attenuated Influenza Vaccines (QLAIV)

Which Trends Are Shaping Growth In The Influenza Vaccines Market?

Leading companies in the influenza vaccine market are implementing sophisticated product advancements, such as quadrivalent seasonal influenza vaccines, to bolster their respiratory vaccine offerings and financial standing. A quadrivalent seasonal influenza vaccine is formulated to offer protection against four distinct influenza viruses, specifically two influenza A viruses and two influenza B viruses. For instance, in September 2023, Clover Biopharmaceuticals Ltd., a China-based biotechnology company, introduced AdimFlu-S (QIS), a quadrivalent seasonal influenza vaccine. This particular vaccine is the sole imported quadrivalent seasonal influenza vaccine approved for administration to individuals aged three years and older in China. Its quadrivalent composition enhances its capacity to attain high vaccine effectiveness, regardless of which influenza B strain becomes seasonally prevalent, in contrast to trivalent options.

Which Organizations Play A Role In The Influenza Vaccines Market Landscape?

Major companies operating in the influenza vaccines market are Pfizer Inc., Merck & Co Inc., Sanofi-Aventis LLC, GlaxoSmithKline plc, Serum Institute of India Private Limited, Seqirus Inc., CSL Limited, Daiichi Sankyo Company Limited, Moderna Inc., Novavax AB, Bharat Biotech International Limited, Valneva SE, Shionogi & Co Ltd., Sinovac Biotech Co Ltd., Walvax Biotechnology Co Ltd., Hualan Biological Engineering Inc., China National Pharmaceutical Group Corporation, Green Cross Corporation, Mitsubishi Tanabe Pharma Corporation, Osivax, Vaxess Technologies Inc., Gamma Vaccines Pty Ltd

Get The Full Influenza Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Where Is The Influenza Vaccines Market Most Concentrated Geographically?

North America was the largest region in the influenza vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Influenza Vaccines Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Browse Through More Reports Similar to the Global Influenza Vaccines Market 2026, By The Business Research Company

Influenza Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Influenza Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Influenza Vaccines Market Expected To Change Between 2026 And 2030?

The influenza vaccines market size has experienced significant growth in recent years. It is forecast to expand from $9.04 billion in 2025 to $9.71 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.4%. The historical increase in the market can be attributed to the rising prevalence of seasonal influenza, limited public awareness in early 2000s, predominance of trivalent vaccines, low global manufacturing capacity, and reliance on traditional egg-based production methods.

The influenza vaccines market size is projected to experience substantial expansion over the upcoming years, reaching $13.13 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.8%. This anticipated growth during the forecast period can be primarily attributed to factors such as the rising uptake of quadrivalent vaccines, the broadening of precision medicine strategies, increasing governmental vaccination programs, advancements in cell-based and recombinant vaccine development, and improvements in cold chain and distribution networks. Key trends expected during the forecast period encompass the optimization of seasonal vaccine formulations, the broadening of pediatric immunization initiatives, a rise in government-backed flu vaccination campaigns, the integration of new adjuvants to boost immunogenicity, and an expansion of vaccine delivery services in home and outpatient settings.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11935&type=smp

Which Major Factors Are Driving The Expansion Of The Influenza Vaccines Market?

The increasing occurrence of seasonal influenza is anticipated to drive forward the influenza vaccine market. Seasonal influenza is characterized as a respiratory ailment triggered by influenza viruses, which commonly circulate and lead to infections during specific periods annually, typically in colder months. This trend stems from factors such as antigenic drift, population susceptibility, environmental elements, insufficient vaccine coverage, and a lack of widespread immunization. Influenza vaccines are instrumental in decreasing seasonal influenza cases by offering protection against the prevailing virus strains. For instance, in November 2023, the Centers for Disease Control and Prevention (CDC), a US-based government agency, disclosed that the 2022-2023 flu season saw approximately 31 million flu-related illnesses, 14 million flu-related medical visits, 360,000 flu-related hospitalizations, and 21,000 flu-related deaths. Consequently, the rising instances of seasonal influenza are fueling the expansion of the influenza vaccine market.

How Is The Influenza Vaccines Market Structured Across Different Segments?

The influenza vaccines market covered in this report is segmented –

1) By Vaccine Type: Inactivated, Live Attenuated

2) By Valency: Quadrivalent, Trivalent

3) By Route Of Administration: Injection, Nasal Spray

4) By Age Group: Pediatric, Adult

5) By Distribution Channel: Hospitals And Pharmacies, Government And Institutional Supply, Other Distribution Channels

Subsegments:

1) By Inactivated: Trivalent Inactivated Vaccines (TIV), Quadrivalent Inactivated Vaccines (QIV)

2) By Live Attenuated: Live Attenuated Influenza Vaccines (LAIV), Quadrivalent Live Attenuated Influenza Vaccines (QLAIV)

Which Trends Are Shaping The Future Of The Influenza Vaccines Market?

Leading companies operating within the influenza vaccine market are adopting advanced product innovations, such as quadrivalent seasonal influenza vaccines, to strengthen their respiratory vaccine franchise and financial profile. A quadrivalent seasonal influenza vaccine is engineered to protect against four distinct flu viruses, encompassing two influenza A viruses and two influenza B viruses. For instance, in September 2023, Clover Biopharmaceuticals Ltd., a biotechnology company based in China, launched AdimFlu-S (QIS), a quadrivalent seasonal influenza vaccine. This particular vaccine stands as the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older across China. The quadrivalent composition of the vaccine enhances its capability to achieve high vaccine effectiveness, regardless of which influenza B strain becomes seasonally prevalent, when compared with trivalent options.

Which Major Players Dominate The Influenza Vaccines Market?

Major companies operating in the influenza vaccines market are Pfizer Inc., Merck & Co Inc., Sanofi-Aventis LLC, GlaxoSmithKline plc, Serum Institute of India Private Limited, Seqirus Inc., CSL Limited, Daiichi Sankyo Company Limited, Moderna Inc., Novavax AB, Bharat Biotech International Limited, Valneva SE, Shionogi & Co Ltd., Sinovac Biotech Co Ltd., Walvax Biotechnology Co Ltd., Hualan Biological Engineering Inc., China National Pharmaceutical Group Corporation, Green Cross Corporation, Mitsubishi Tanabe Pharma Corporation, Osivax, Vaxess Technologies Inc., Gamma Vaccines Pty Ltd

Read the full influenza vaccines market report here:

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Which Region Currently Holds The Largest Share Of The Influenza Vaccines Market?

North America was the largest region in the influenza vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Influenza Vaccines Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11935&type=smp

Browse Through More Reports Similar to the Global Influenza Vaccines Market 2026, By The Business Research Company

Influenza Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Influenza Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the influenza vaccines market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Influenza Vaccines Market’s size between 2026 and 2030?

The influenza vaccines market has experienced robust expansion in recent times. This market is projected to expand from $9.04 billion in 2025 to $9.71 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.4%. Historically, this growth was driven by factors such as the increasing prevalence of seasonal influenza, a limited public awareness during the early 2000s, the widespread use of trivalent vaccines, constrained global manufacturing capabilities, and a dependence on conventional egg-based production methods.

The influenza vaccines market size is expected to experience robust expansion in the coming years. It is forecast to achieve a valuation of $13.13 billion by 2030, advancing at a compound annual growth rate (CAGR) of 7.8%. This growth over the projection period is attributed to several factors, including the increasing uptake of quadrivalent vaccines, the broader application of precision medicine approaches, escalating government-led vaccination efforts, the progression of cell-based and recombinant vaccine development, and enhancements in cold chain and distribution infrastructure. Prominent trends for the forecast period include optimizing seasonal vaccine formulations, broadening pediatric immunization initiatives, an uptick in government-funded influenza vaccination campaigns, the integration of novel adjuvants for improved immunogenicity, and an increase in home-based and outpatient vaccine delivery methods.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11935&type=smp

Which Drivers Are Shaping Strategic Decisions In The Influenza Vaccines Market?

An anticipated increase in seasonal influenza cases is projected to drive the expansion of the influenza vaccine market moving ahead. Seasonal influenza is defined as a respiratory ailment stemming from influenza viruses, which commonly spread and lead to infections during particular periods annually, generally in cooler seasons. This trend has emerged due to antigenic drift, the vulnerability of populations, environmental influences, insufficient vaccine penetration, and the absence of widespread immunization. Influenza vaccinations contribute to lowering the occurrences of seasonal influenza by offering immunity against the currently circulating viral strains. For instance, in November 2023, the Centers for Disease Control and Prevention (CDC), a government body located in the US, disclosed that the 2022-2023 flu season saw roughly 31 million flu-related illnesses, 14 million flu-related medical visits, 360,000 flu-related hospitalizations, and 21,000 flu-related deaths. Consequently, the increasing frequency of influenza seasons is fueling the expansion of the influenza vaccines market.

What Segment Categories Are Covered In The Influenza Vaccines Market?

The influenza vaccines market covered in this report is segmented –

1) By Vaccine Type: Inactivated, Live Attenuated

2) By Valency: Quadrivalent, Trivalent

3) By Route Of Administration: Injection, Nasal Spray

4) By Age Group: Pediatric, Adult

5) By Distribution Channel: Hospitals And Pharmacies, Government And Institutional Supply, Other Distribution Channels

Subsegments:

1) By Inactivated: Trivalent Inactivated Vaccines (TIV), Quadrivalent Inactivated Vaccines (QIV)

2) By Live Attenuated: Live Attenuated Influenza Vaccines (LAIV), Quadrivalent Live Attenuated Influenza Vaccines (QLAIV)

What Industry Trends Are Transforming The Influenza Vaccines Market?

Leading companies in the influenza vaccine market are implementing advanced product innovations, such as quadrivalent seasonal influenza vaccines, to bolster their respiratory vaccine product lines and financial standing. A quadrivalent seasonal influenza vaccine is engineered to protect against four different flu viruses, specifically two influenza A viruses and two influenza B viruses. For example, in September 2023, Clover Biopharmaceuticals Ltd., a China-based biotechnology firm, introduced AdimFlu-S (QIS), a quadrivalent seasonal influenza vaccine. This vaccine represents the only imported quadrivalent seasonal influenza vaccine approved for individuals aged three years and older in China. The quadrivalent formulation of the vaccine enhances its potential to achieve high vaccine effectiveness, regardless of which influenza B strain becomes seasonally widespread, particularly when compared with trivalent varieties.

Which Key Players Are Driving Competition In The Influenza Vaccines Market?

Major companies operating in the influenza vaccines market are Pfizer Inc., Merck & Co Inc., Sanofi-Aventis LLC, GlaxoSmithKline plc, Serum Institute of India Private Limited, Seqirus Inc., CSL Limited, Daiichi Sankyo Company Limited, Moderna Inc., Novavax AB, Bharat Biotech International Limited, Valneva SE, Shionogi & Co Ltd., Sinovac Biotech Co Ltd., Walvax Biotechnology Co Ltd., Hualan Biological Engineering Inc., China National Pharmaceutical Group Corporation, Green Cross Corporation, Mitsubishi Tanabe Pharma Corporation, Osivax, Vaxess Technologies Inc., Gamma Vaccines Pty Ltd

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Which Region Is Projected To Lead The Influenza Vaccines Market During The Forecast Period?

North America was the largest region in the influenza vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Influenza Vaccines Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11935&type=smp

Browse Through More Reports Similar to the Global Influenza Vaccines Market 2026, By The Business Research Company

Influenza Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-vaccines-global-market-report

Influenza Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model